Table 1.
Characteristics | N | Total |
---|---|---|
Age (years), mean (SD) | 20 | 45 (14.2) |
Gender (female), n (%) | 20 | 11 (55) |
Race (white), n (%) | 20 | 18 (90) |
Duration of psoriasis diagnosis (years), mean (SD)a | 19 | 18 (14) |
Duration of genital psoriasis diagnosis (years), mean (SD)a | 20 | 7.5 (9.7) |
Body surface area, mean (SD)a | 15 | 10.4 (12.7) |
Currently receiving treatment for genital psoriasis,a,b,c n (%) | 20 | 14 (70) |
Biologics including investigational products | – | 11 (55) |
Topicals (including OTC) | – | 7 (35) |
Phototherapy | – | 0 |
Self-reported genital psoriasis symptom severity at its worst over the past 3 months, n (%) | 20 | |
0–1 (0 = clear) | – | 0 |
2–3 | – | 6 (30) |
4–5 (5 = severe) | – | 14 (70)d |
Self-reported overall psoriasis symptom severity at its worst over the past 3 months, n (%) | 20 | |
0–1 (0 = clear) | – | 1 (5) |
2–3 | – | 6 (30) |
4–5 (5 = severe) | – | 13 (65) |
Self-reported current localization of psoriasis other than genital psoriasis,c n (%) | 20 | |
Scalp | – | 17 (85) |
Hands, feet, and/or nails | – | 13 (65) |
Face | – | 11 (55) |
Skin folds (i.e., armpits, under the breasts) | – | 10 (50) |
Other (responses included: limbs, buttocks, trunk, knees, elbow, ears) | – | 14 (65) |
Sexual activity status, n (%) | 20 | |
Active | – | 9 (45) |
Not active | – | 9 (45) |
Not askede | – | 2 (10) |
OTC over the counter, SD standard deviation
aPatient clinical characteristics as reported by clinicians
b N = 13 patients self-reported that they were currently receiving treatment for psoriasis. From the clinical forms, current treatment was documented by clinic site staff for N = 14 patients
cResponses not mutually exclusive
dAll patients met study criteria at screening of self-reported genital psoriasis (Patient Global Assessment ≥ 4, 6-point scale); these data report status at the time of the interview
ePer interviewers’ judgment, the question was not asked due to auditory cues, conversation flow, and patient’s apparent lack of comfort with sensitive topics